RxDoctor Payments Data

Indira Devu, MD

Internal Medicine · Marietta, GANPI 1871530139

Payments from drug & device makers

$26,965in general payments, 2019–2025

Across 146 payments — averaging $184.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$22K
  • Amgen$2K
  • Astrazeneca UK Limited$1K
  • Novo Nordisk$878
  • Pfizer$197
  • AbbVie$147
  • plus $811 from 11 others

What the payments were for

  • Food & beverage$3,086100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca11$21,577
Amgen(2 entities)38$2,001
Astrazeneca UK Limited1$1,354
Novo Nordisk37$878
Pfizer10$197
AbbVie(2 entities)9$147
Lilly USA, LLC6$124
Otsuka America Pharmaceutical, Inc.6$122
Exact Sciences6$114
GSK6$90
Sanofi-aventis U.S. LLC4$87
Amarin Pharma, Inc.4$80
Bayer3$67
Dexcom, Inc.2$52
Omeza LLC1$31
Linus Health, Inc.1$24
Arbor Pharmaceuticals, Inc.1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,965 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$102,661
Medicare patients
61
Services billed
1,353

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide57$110,560
OzempicSemaglutide36$47,400
GemtesaVibegron32$24,008
LinzessLinaclotide22$19,381
CreonLipase/Protease/Amylase13$14,588
FarxigaDapagliflozin Propanediol11$8,587
Repatha SyringeEvolocumab13$7,327
SymbicortBudesonide/Formoterol Fumarate23$5,301
VascepaIcosapent Ethyl12$4,425
Levemir FlexpenInsulin Detemir13$2,550
Atorvastatin Calcium250$1,980
FenofibrateFenofibrate Nanocrystallized65$1,599
Nifedipine ErNifedipine37$1,458
Nebivolol Hcl22$1,221
Albuterol Sulfate HfaAlbuterol Sulfate45$1,119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$878$157,96093 claims
AbbVieLinzess, Creon$147$33,96935 claims
AstraZenecaFarxiga, Symbicort$21,577$13,88834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →